Dose Characterization of the Investigational Anticancer Drug Tigilanol Tiglate (EBC-46) in the Local Treatment of Canine Mast Cell Tumors

Frontiers in Veterinary Science- Switzerland

doi 10.3389/fvets.2019.00106

Full Text

Abstract

Available in

Categories

Date

April 9, 2019

Authors

Justine Campbell

Victoria Gordon

Publisher

Frontiers Media SA

Related search

Optimising Intratumoral Treatment of Head and Neck Squamous Cell Carcinoma Models With the Diterpene Ester Tigilanol Tiglate

Investigational New Drugs

English

Canine Mast Cell Tumors: A Comparison of Staining Techniques

Journal of Veterinary Diagnostic Investigation

English

Evaluation of the Kinase Domain of C-Kit in Canine Cutaneous Mast Cell Tumors

Cancer Research

English

Immunohistochemical and Clinical Evaluation of P53 in Canine Cutaneous Mast Cell Tumors

Veterinary Pathology

English

Variation Among Pathologists in Histologic Grading of Canine Cutaneous Mast Cell Tumors

Journal of Veterinary Diagnostic Investigation

English

Nanog Expression and Proliferation Indices in Canine Cutaneous Mast Cell Tumors

Veterinary Pathology

English

The Phosphoinositide 3-Kinase Pathway Is Crucial for the Growth of Canine Mast Cell Tumors

Journal of Veterinary Medical Science

English

Detection of C-Kit Mutations in Canine Mast Cell Tumors Using Fluorescent Polyacrylamide Gel Electrophoresis

Journal of Veterinary Diagnostic Investigation

English

Neuroendocrine (Merkel) Cell Tumors of the Canine Oral Cavity

Veterinary Pathology

English